Connect with us
Financial Press
the-wall-street-journal:-fda-grants-emergency-use-status-to-abbott’s-$5-covid-19-rapid-antigen-test
the-wall-street-journal:-fda-grants-emergency-use-status-to-abbott’s-$5-covid-19-rapid-antigen-test

Breaking

The Wall Street Journal: FDA grants emergency-use status to Abbott’s $5 COVID-19 rapid antigen test

The Wall Street Journal

Plans to ship 50 million tests in October, massively expanding U.S. testing capacity

Abbott says its BinaxNOW COVID-19 Ag Card is a rapid, reliable and affordable tool for detecting active coronavirus infections at massive scale.


Abbott Laboratories

The U.S. Food and Drug Administration has granted emergency-use authorization to Abbott Laboratories for a $5 rapid-response COVID-19 antigen test that is roughly the size of a credit card.

The low-cost, rapid-response test could be administered in a doctor’s or school nurse’s office and uses technology similar to home pregnancy tests. It returns results in about 15 minutes.

The emergency approval comes as demand grows for greater access to COVID-19 diagnostic tools that deliver results in minutes, rather than days to help quickly contain infections.

Abbott
ABT,
+0.70%

said Wednesday it plans to ship tens of millions of the newly approved tests in September, with plans to increase production to 50 million tests in October. If the company is able to do so, the October total would amount to roughly double the number of tests performed in the U.S. in July.

Some public-health officials and lab executives say lower-cost rapid tests that can be produced at scale are an important factor in the country’s ability to return to work and school.

An expanded version of this report appears on WSJ.com.

Also popular on WSJ.com:

Donald Trump presides over GOP remake in his image.

Wisconsin identifies officer who shot Jacob Blake.

- END THEIA POST SLIDER -->

Written By

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

Breaking

Well, this is unfortunate… The story you requested could not be found. To find what you’re looking for, try one of these options. MarketWatch...

Breaking

Well, this is unfortunate… The story you requested could not be found. To find what you’re looking for, try one of these options. MarketWatch...

Breaking

Well, this is unfortunate… The story you requested could not be found. To find what you’re looking for, try one of these options. MarketWatch...

Breaking

Well, this is unfortunate… The story you requested could not be found. To find what you’re looking for, try one of these options. MarketWatch...